Details

Autor(en) / Beteiligte

• Zand, Ladan, MD
• Kattah, Andrea, MD
• Fervenza, Fernando C., MD, PhD
• Smith, Richard J.H., MD
• Nasr, Samih H., MD
• Zhang, Yuzhou, PhD
• Vrana, Julie A., PhD
• Leung, Nelson, MD
• Cornell, Lynn D., MD
• Sethi, Sanjeev, MD, PhD

Titel

C3 Glomerulonephritis Associated With Monoclonal Gammopathy: A Case Series

Ist Teil von

• American journal of kidney diseases, 2013-09, Vol.62 (3), p.506-514

Ort / Verlag

New York, NY: Elsevier Inc

Erscheinungsjahr

2013

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• Background C3 glomerulonephritis (GN) is a proliferative GN resulting from glomerular deposition of complement factors due to dysregulation of the alternative pathway of complement. Dysregulation of the alternative pathway of complement may occur as a result of mutations or functional inhibition of complement-regulating proteins. Functional inhibition of the complement-regulating proteins may result from a monoclonal gammopathy. Study Design Case series. Setting & Participants 32 Mayo Clinic patients with C3 GN, 10 (31%) of whom had evidence of a monoclonal immunoglobulin in serum. Outcomes Clinical features, hematologic and bone marrow biopsy findings, kidney biopsy findings, kidney measures, complement pathway abnormalities, treatment, and follow-up of patients with C3 GN that was associated with a monoclonal gammopathy. Results Mean age of patients with C3 GN associated with monoclonal gammopathy was 54.5 years. Bone marrow biopsy done in 9 patients revealed monoclonal gammopathy of undetermined significance in 5 patients, small lymphocytic lymphoma/chronic lymphocytic leukemia in one patient, and no abnormal clones in the other 3 patients. Kidney biopsy showed membranoproliferative GN with bright capillary wall C3 staining in all 10 patients. Evaluation of the alternative pathway of complement showed abnormalities in 7 of 9 patients tested. No mutation in complement-regulating proteins was detected in any patient. As an index case, one patient with C3 GN and chronic lymphocytic leukemia was treated with rituximab, cyclophosphamide, vincristine, and prednisone, and one patient with C3 GN and monoclonal gammopathy of undetermined significance was treated with dexamethasone and bortezomib. Both patients showed significant decreases in hematuria and proteinuria and stabilization of kidney function. Limitations Studies to show evidence of direct activation of the alternative pathway by monoclonal immunoglobulin were not done. Conclusions The study highlights the association of C3 GN and monoclonal gammopathy, in particular in the older population, and the importance of targeting the underlying hematologic malignancy as an approach to treating C3 GN.